Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (ERCI) network

Guillaume Moulis*, Nichola Cooper, Waleed Ghanima, Tomás González-López, Thomas Kühne, Maria L. Lozano, Marc Michel, Drew Provan, Francesco Zaja, Nathalie Aladjidi, Christian Fynbo Christiansen, Henrik Frederiksen, John Grainger, Vickie McDonald, Susan Robinson, Alexandra Schifferli, Francesco Rodeghiero


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

3 Downloads (Pure)
TidsskriftBritish Journal of Haematology
Udgave nummer5
Sider (fra-til)633-638
StatusUdgivet - jun. 2022

Bibliografisk note

Funding Information:
Alexandra Schifferli received board honoraria from Sobi and Novartis and received research funds from Amgen. Christian Fynbo Christiansen did not report any personal conflicts of interest but is an employee of Aarhus University that received research grants from Amgen. Drew Provan received research support from Amgen and Novartis; honoraria from Amgen, Argenx, Novartis, Sobi and UCB; consultancies from Argenx, MedImmune, Ono, Sobi, and UCB. Francesco Rodeghiero is in the Advisory Board/Speakers’ Bureau of Amgen, Argenx, Novartis and UCB. Guillaume Moulis received meeting attendance grants from Amgen, Grifols and Novartis; he is co‐ordinator of research studies granted by Amgen, CSL Behring, Grifols, Novartis and Sanofi. He participated in educational sessions funded by Amgen, Grifols and Novartis, and on boards for Amgen, Argenx, Novartis, and Sobi. Henrik Frederiksen received research grants outside this work from Alexion, Gilead, Abbvie, Janssen Pharmaceuticals, and Novartis. Maria L. Lozano reports grants and personal fees from Amgen and from Terumo S.A., and personal fees from Alexion, Amgen, Argenx BV, Celgene, GlaxoSmithKline, Grifols, Novartis, Sobi, UCB Biopharma. Tomás González‐López received Advisory Board honoraria from Amgen, Novartis and Momenta, and speaker’s honoraria and research support from Amgen and Novartis. Thomas Kühne reports research funds from Amgen and Novartis and Advisory Boards for Amgen, Argenx, Novartis, SOBI and UCB. Waleed Ghanima reports fees for participation in Advisory boards from Amgen, Novartis, Pfizer, Principia Biopharma Inc. ‐ a Sanofi Company, Sanofi, SOBI, Griffols, UCB, Argenx; lecture honoraria from Amgen, Novartis, Pfizer, Bristol Myers Squibb, SOBI, Griffols, Sanofi; and research grants from Bayer and BMS/Pfizer. Vickie McDonald advisory work: Novartis, Sobi, Bayer, Amgen; speakers fees: Novartis, Amgen, Sobi; research grants: Rigel, Grifols. All other authors did not report any conflict of interests

Funding Information:
We thank the sponsors of the registries listed in this manuscript: CARMEN‐France: French Society of Internal Medicine, Amgen, CSL Behring, Grifols and Novartis. The OBS'CEREVANCE cohort has been supported by the French Ministery of Health (Rare Disease Plan), patient organisations and Novartis. The PARC‐ITP and the AYAS Project have been funded by the Stiftung zur Förderung Medizinischer und Biologischer Forschung (Arlesheim, CH), the Stiftung für Hämatologische Forschung (Basel, CH) and the Platelet Disorder Support Association (Cleveland, OH, USA). The UK IT ITP has received funding from the ITP Support association, Grifols and Rigel. The Italian adult ITP registry is supported by the Gruppo Italiano Malattie EMatologiche dell’Adulto (GIMEMA) Foundation, the Haematology Project Foundation and Novartis. The Norwegian ITP registry received support from Novartis, UCB and the Norwegian Medical Association.